Sign in to continue:

Monday, March 2nd, 2026

H&H International Holdings Announces Board Meeting to Approve 2025 Annual Results and Final Dividend on March 24, 2026 1

H&H International Holdings Announces Board Meeting to Consider 2025 Annual Results and Final Dividend

H&H International Holdings Schedules Board Meeting to Approve 2025 Annual Results and Final Dividend

Key Points:

  • Board Meeting Date: Health and Happiness (H&H) International Holdings Limited (“H&H” or “the Company”) has announced that its Board of Directors will convene on Tuesday, 24 March 2026 at 9:00 a.m.
  • Location: The meeting will be held at Suites 4007-09, 40th Floor, One Island East, Taikoo Place, 18 Westlands Road, Quarry Bay, Hong Kong.
  • Main Agenda: The primary purpose of this meeting is to consider and approve the annual results of the Group for the year ended 31 December 2025.
  • Dividend Recommendation: The Board will also consider the recommendation of a final dividend, if any, for shareholders.
  • Other Business: The Board may also discuss and transact any other business during this meeting.

What Shareholders Need to Know

  • Potential Price Sensitivity: The outcome of this Board meeting could have a significant impact on the Company’s share price. The approval of annual results typically provides investors crucial insights into the Company’s financial health. Additionally, the declaration (or absence) of a final dividend is a key event that can influence investor sentiment and the market valuation of H&H.
  • Dividend Decision: Investors should pay particular attention to the Board’s decision regarding the final dividend. A higher or lower-than-expected dividend could affect the Company’s attractiveness to income-focused investors and impact share price performance.
  • Management and Governance: The announcement also provides a comprehensive list of the current members of the Board, including Executive Directors (Mr. Luo Fei and Mr. Wang Yidong), Non-Executive Directors (Mrs. Laetitia Albertini, Dr. Zhang Wenhui, Mr. Luo Yun, and Mrs. Mingshu Zhao Wiggins), and Independent Non-Executive Directors (Mr. Tan Wee Seng, Mrs. Lok Lau Yin Ching, and Professor Ding Yuan). This ensures clarity regarding the Company’s leadership and governance structure for investors.

Summary for Investors

H&H International Holdings’ upcoming Board meeting is a key event for shareholders and potential investors, as it will determine the Company’s financial results for the full year 2025 and address the possibility of a final dividend. Both the financial outcomes and dividend decision are material events that could influence the trading of H&H shares. Investors are advised to monitor the results of this meeting closely, as the announcements following the meeting are likely to be price sensitive and may affect the Company’s valuation.


Disclaimer: The information contained in this article is based on an official company announcement. Investors should not rely solely on this article for investment decisions and are encouraged to consult the original documents and seek professional advice before making investment choices. The Company and the Hong Kong Stock Exchange accept no responsibility for any loss arising from reliance on the contents of this article.

View H&H INTL HLDG Historical chart here



San Miguel Brewery Hong Kong Limited Announces 2025 Annual Results: Strong Revenue Growth, Improved Profitability, and Business Outlook

San Miguel Brewery Hong Kong Limited 2025 Annual Results: Investor Highlights and Analysis San Miguel Brewery Hong Kong Limited Announces Strong Turnaround in 2025 Annual Results Key Financial Highlights Net Profit Reversal: The Group...

Tian Tu Capital Completes Major Transaction: Disposal of 86.96% Minority Interest in Yoplait China for RMB 1.57 Billion

Tian Tu Capital Completes Major Disposal of Yoplait China Stake Tian Tu Capital Completes Major Disposal of Yoplait China Stake Key Highlights for Investors Completion of Major Transaction: Tian Tu Capital Co., Ltd. (“the...

Sino Biopharm’s Rovadicitinib Tablet Approved in China as First-Line Treatment for Myelofibrosis, Shows Superior Efficacy and Safety 12

Sino Biopharmaceutical’s Rovadicitinib Tablet Approved for Marketing in China: Key Details for Investors Sino Biopharmaceutical’s Rovadicitinib Tablet Receives Landmark Approval in China Key Highlights and Investor-Relevant Insights First-in-Class Approval: Sino Biopharmaceutical Limited (HKEX: 1177)...

   Ad